z-logo
open-access-imgOpen Access
Association Between Ki67 After Neoadjuvant Chemotherapy and Disease-Free Survival in Breast Cancer.
Author(s) -
Aan Wahyu Setiawan,
Mulawan Umar,
Erial Bahar
Publication year - 2021
Publication title -
sriwijaya journal of surgery
Language(s) - English
Resource type - Journals
ISSN - 2722-3558
DOI - 10.37275/sjs.v4i2.57
Subject(s) - breast cancer , medicine , chemotherapy , oncology , breast carcinoma , retrospective cohort study , neoadjuvant therapy , cancer , stage (stratigraphy) , disease , paleontology , biology
Background: Post Chemotherapy Ki67 in recent year has been investigated as a predictive and prognostic factor in locally advanced breast cancer patient undergoing neoadjuvant chemotherapy. Objectives: To describe the relationship between post-chemotherapy Ki67 and disease-free survival after neoadjuvant chemotherapy in patients with locally advanced breast cancer at Dr. Hospital. Mohammad Hoesin Palembang. Methods: This study is an analytical observational study with prognostic test design conducted in 30 stage III B breast cancer patient. A retrospective search of a prospectively maintained clinical database was performed to identify patient treated with neoadjuvant chemotherapy at the Mohammad Hoesin Hospital. The expression of Ki67 was assessed using immunohisto-chemistry in post therapy surgical excision specimen. Results: From 30 patients, there was a significant relationship between Post Chemotherapy Ki67 and disease- free survival in patients with locally advanced breast cancer (r = -0,742, p = 0.000). The cut off point value of Ki67 was 27,5% with an area under curve (AUC) of 0,716. The results of the post-chemotherapy Ki67 prognosis test included sensitivity 64%, specificity 60%, Positive Predictive Value 88,9%, Negative Predictive Value 25%, accuracy 63,3%. Conclusion: There is a significant relationship between Post Chemotherapy Ki67 to disease free survival and Post Chemotherapy Ki67 can be used as a prognostic biomarker in breast carcinoma patients undergoing neoadjuvant chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here